David W. Shen

Proteologix is an innovative biotech company focused on immunology and inflammation diseases (I&I). We discover and develop highly differentiated multi-specific, multi-functional antibody drugs to break efficacy ceiling and, at the same time, to extend the half-life of the molecules for less frequent dosing. We are a clinical ready company with lead programs ready for clinical trials in atopic dermatitis, asthma, and other I&I diseases. Proteologix was recently acquired by J&J for $850M plus milestone in less than three years after initiation of the company in 2021.

David is a member of Executive Committee at NGM that sets the strategy for first-in-class, innovative biologics and the pipeline portfolio. He is head of biologic research (antibody and protein sciences), bioanalytical assays (PK and immunogenicity assays), process development,and CMC up to commercialization.

Vice President, Global Head of Biologics Development in the Branded Products R&D at TEVA Pharmaceuticals, David is a critical member of the leadership team that sets the strategy for BioSimilars, BioBetters and innovative biologics including their pipeline portfolio. In this capacity, he oversees research, process development, bioassay Center of Excellence (including but not limited to functional assays, PK assays, potency assays, immunogenicity assays), and CMC up to phase III clinical materials.

Prior to TEVA, David worked with Merck serving as Executive Director of Biologics Research and GlycoFi overseeing two research sites with more than 100 staff supporting all 7 therapeutic areas across all research labs. His department worked on innovative therapeutic antibody, protein based drug and follow-on biologics (biosimilars and biobetters). David led his leadership team to develop a clear strategy to position Merck Biologics in the right direction for growth through balancing their portfolio with both innovative and follow-on biologics and championing for corporate partnerships to further balance the Biologics Portfolio.

His professional career started at Amgen where David held positions of increasing responsibilities and most recently became Director and Head of Protein Science Department at the San Francisco research facility and led a group working on therapeutic antibody, protein based drug discovery for oncology, inflammation, metabolic disorders, and neurosciences. Before moving to San Francisco, he was a group leader for antibody engineering, where they played key roles for more than 8 antibodies currently in early and late stage clinical trials. His group developed a novel Mammalian Antibody Display technology for antibody discovery/selection, which for the first time allows functional display of full length IgG on mammalian cell surface.